Synapse Biomedical

Focus: Synapse Biomedical is a publicly-traded biotechnology company specializing in implantable diaphragm pacing systems for respiratory and neurological conditions. The company operates a focused product portfolio targeting high-impact indications in neurology and respiratory disease.

Neurology Respiratory Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Synapse Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow Synapse Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

NeuRx® Diaphragm Pacing System™

Amyotrophic Lateral Sclerosis (ALS)

Growth

Lead program in Phase 2 development targeting progressive neurodegenerative disease with no cure and high unmet need.

NeuRx DPS

Spinal Cord Injury

Help build intelligence for Synapse Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Novel medical device platform with multiple late-stage programs in high-need areas (ALS, spinal cord injury, respiratory failure)
Public company status provides equity upside and financial transparency absent in early-stage biotech
Focused portfolio allows deep specialization in neuromodulation and respiratory physiology

Watch Out For

Minimal hiring activity (only 1 active job posting) suggests company is not in growth mode or is fully staffed
Limited pipeline transparency—most programs lack phase designation, indicating early-stage or exploratory status beyond Phase 2 NeuRx DPS for ALS
No published research output on record (0 publications) raises questions about scientific visibility and peer-reviewed validation

Generated by Claude from Synapse Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Addresses severe paralysis and respiratory compromise in spinal cord injury population with significant market opportunity.

TransAeris System

Ventilator-Induced Diaphragm Dysfunction

Growth

Targets critical care patient population dependent on mechanical ventilation with potential de-weaning applications.